Kalvista Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kalvista Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013460
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kalvista Pharmaceuticals Ltd (Kalvista Pharma), formerly Kalvista Limited, is a pharmaceutical company which focuses on the discovery, development and commercialization of small molecule serine protease inhibitors. It develops a proprietary portfolio of small molecule plasma kallikrein inhibitors which are used for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME). Kalvista Pharma also develops the clinical and advanced pre-clinical product pipeline that targets multiple routes used to treat the HAE and DME. The company also operates through its office in Boston, the US. Kalvista Pharma is headquartered in Salisbury, England, the UK.

Kalvista Pharmaceuticals Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Kalvista Acquires Plasma Kallikrein Inhibitors from Vantia Therapeutics 10
Venture Financing 11
KalVista Pharma Raises USD33 Million in Series B Financing 11
KalVista Pharma Secures US$13.2 Million In Series A Financing 12
Partnerships 13
KalVista Pharma Enters Into Research Agreement With JDRF 13
Acquisition 14
Carbylan Therapeutics Acquires KalVista Pharma 14
Kalvista Pharmaceuticals Ltd – Key Competitors 16
Kalvista Pharmaceuticals Ltd – Key Employees 17
Kalvista Pharmaceuticals Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Nov 29, 2016: KalVista appoints chief scientific officer 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kalvista Pharmaceuticals Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Kalvista Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kalvista Acquires Plasma Kallikrein Inhibitors from Vantia Therapeutics 10
KalVista Pharma Raises USD33 Million in Series B Financing 11
KalVista Pharma Secures US$13.2 Million In Series A Financing 12
KalVista Pharma Enters Into Research Agreement With JDRF 13
Carbylan Therapeutics Acquires KalVista Pharma 14
Kalvista Pharmaceuticals Ltd, Key Competitors 16
Kalvista Pharmaceuticals Ltd, Key Employees 17
Kalvista Pharmaceuticals Ltd, Subsidiaries 18

★海外企業調査レポート[Kalvista Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UCB Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a bio-pharmaceutical company that develops, manufactures and markets genetic engineering drugs. The company offers bio-pharmaceutical products in the field of genetic engineering, p …
  • Orsted AS (ORSTED):電力:M&Aディール及び事業提携情報
    Summary Orsted AS (Orsted) formerly Dong Energy A/S, is an integrated energy company that procures, produces, distributes and trades energy and energy related products. It generates electricity and heat using conventional fuel and wind energy sources. The company also develops, constructs, owns and …
  • Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析
    Summary Prana Biotechnology Ltd (Prana Biotech) is a pharmaceutical company that develops therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer's disease, brain cancer, and other major age-related degenerative disorders. It is developing first-in-class therapies fo …
  • STATS UK Ltd:企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Compass Minerals International Inc (CMP):企業の財務・戦略的SWOT分析
    Compass Minerals International Inc (CMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • New Zealand Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary New Zealand Pharmaceuticals Ltd (NZP) a subsidiary of Archer Capital, manufactures and supplies pharmaceutical intermediates and diagnostic products for pharmaceutical and microbiological media companies. It also offers biochemicals and natural extracts for health, cosmetic, biotechnology, f …
  • Honkarakenne Oyj (HONBS):企業の財務・戦略的SWOT分析
    Honkarakenne Oyj (HONBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CorEnergy Infrastructure Trust, Inc. (CORR)-石油・ガス分野:企業M&A・提携分析
    Summary CorEnergy Infrastructure Trust, Inc. (CorEnergy) is an energy infrastructure real estate investment trust. The company owns assets in the midstream and downstream US energy sectors that perform functions, such as pipelines, storage terminals, and transmission and distribution assets. Its por …
  • E.ON SE:企業の戦略・SWOT・財務情報
    E.ON SE - Strategy, SWOT and Corporate Finance Report Summary E.ON SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Vanderbilt University Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Vanderbilt University Medical Center (VUMC), a subsidiary of Vanderbilt University is a healthcare service provider that offers patient care, research and bio-medical education. The center’s services include adult emergency services, case management, corporate health services, adult psychiat …
  • Xcel Energy Inc (XEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • United Breweries Limited:企業の戦略・SWOT・財務情報
    United Breweries Limited - Strategy, SWOT and Corporate Finance Report Summary United Breweries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • UTair Aviation:企業の戦略・SWOT・財務情報
    UTair Aviation - Strategy, SWOT and Corporate Finance Report Summary UTair Aviation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Simcere Pharmaceutical Group-製薬・医療分野:企業M&A・提携分析
    Summary Simcere Pharmaceutical Group (Simcere) is a drug discovery company that manufactures and supplies branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas including anti-tumor, central nervous, anti-infection, cardiovascular, skeletal muscle, …
  • Laboratorios SALVAT SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratorios SALVAT SA (SALVAT) is a pharmaceutical company with focus on the development and commercialization of innovative medicines. The company manufactures drugs in various segments such as personal healthcare, digestive / metabolism, urological conditions, ophthalmological diseases, E …
  • Alamo Group, Inc.:戦略・SWOT・企業財務分析
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Euro India Fresh Foods Ltd (EIFFL):企業の財務・戦略的SWOT分析
    Euro India Fresh Foods Ltd (EIFFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Bank of Ireland:戦略・SWOT・企業財務分析
    Bank of Ireland - Strategy, SWOT and Corporate Finance Report Summary Bank of Ireland - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • PhoenixBio Co Ltd (6190)-製薬・医療分野:企業M&A・提携分析
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services which include dosing of test-compounds, sampling, in-life phase trials, chemical analysis, measurement of human albumin levels, and metabolic enzymes and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆